OTCMKTS:HYPMY - Hypera Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$7.27
▲ +0.16 (2.25%)

This chart shows the closing price for HYPMY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hypera Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HYPMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HYPMY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Hypera in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.27.

This chart shows the closing price for HYPMY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Hypera.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/29/2020HSBCUpgradeHold ➝ Buy
(Data available from 6/21/2016 forward)
Hypera logo
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers branded prescription products under the Mantecorp Farmasa, Episol, Predsim, Alivium, Lisador, Rinosoro, Celestamine, Maxsulid, Diprospan, Mioflex-A, and Addera D3 brands; dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. The company also provides nutrition, sweeteners, and vitamin supplement products under the Tamarine, Vitasay 50+, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Torsilax, Neosoro, Doralgina, Flavonid, and Histamin brands. It sells its products through distributors and wholesalers. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.
Read More

Today's Range

Now: $7.27
Low: $7.11
High: $7.27

50 Day Range

MA: $6.63
Low: $6.07
High: $7.49

52 Week Range

Now: $7.27
Low: $4.33
High: $7.76

Volume

5,009 shs

Average Volume

13,336 shs

Market Capitalization

$4.60 billion

P/E Ratio

18.18

Dividend Yield

1.97%

Beta

0.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Hypera?

The following sell-side analysts have issued research reports on Hypera in the last twelve months: HSBC Holdings plc.
View the latest analyst ratings for HYPMY.

What is the current price target for Hypera?

0 Wall Street analysts have set twelve-month price targets for Hypera in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Hypera in the next year.
View the latest price targets for HYPMY.

What is the current consensus analyst rating for Hypera?

Hypera currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HYPMY will outperform the market and that investors should add to their positions of Hypera.
View the latest ratings for HYPMY.

What other companies compete with Hypera?

How do I contact Hypera's investor relations team?

Hypera's physical mailing address is AV. MAGALHAES DE CASTRO 4800 - 24¿ ANDAR EDIFICIO CONTINENTAL TOWER, SAO PAULO D5, 05676-120. The company's listed phone number is 55-11-3627-4206 and its investor relations email address is [email protected] The official website for Hypera is www.hyperapharma.com.br.